Evidence map›Paper›PMID 39422732›Full record

ArticleBasic research in cardiology2024

The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning.

Petra Kleinbongard, Carlos Galán Arriola, Lina Badimon, Veronica Crisostomo, Zoltán Giricz, Mariann Gyöngyösi, Gerd Heusch, Borja Ibanez, Attila Kiss, Dominique P V de Kleijn and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Basic research in cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Petra Kleinbongard *Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany. petra.kleinbongard@uk-essen.de.ORCID 0000-0003-3576-3772
Carlos Galán Arriola *Centro Nacional de Investigaciones Cardiovasculares Carlos III, CIBER de Enfermedades Cardiovasculares (CIBERCV), Melchor Fernández Almagro 9, 28029, Madrid, Spain. carlos.galan@cnic.es.ORCID 0000-0001-7403-8974
Lina BadimonResearch Institute Hospital de La Santa Creu I Sant Pau-IIB Sant Pau, and CIBER Enfermedades Cardiovasculares, Barcelona, Spain.ORCID 0000-0002-9162-2459
Veronica CrisostomoCardiovascular Area, Jesús Usón Minimally Invasive Surgery Centre (CCMIJU), Cáceres, Spain.ORCID 0000-0003-1740-7029
Zoltán GiriczCardiovascular and Metabolic Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-2036-8665
Mariann GyöngyösiDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090, Vienna, Austria.ORCID 0000-0002-7083-2107
Gerd HeuschInstitute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany.ORCID 0000-0001-7078-4160
Borja IbanezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.ORCID 0000-0002-5036-254X
Attila KissLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-4652-1998
Dominique P V de KleijnDepartment of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-2714-2140
Bruno K PodesserLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4641-7202
Rafael Ramírez CarracedoUnidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, Madrid, Spain.ORCID 0000-0002-8391-2245
Antonio Rodríguez-SinovasCardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0003-2930-8773
Marisol Ruiz-MeanaCardiovascular Diseases Research Group, Department of Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-4067-4638
Francisco M Sanchez MargalloCIBER de Enfermedades Cardiovasculares (CIBERCV), RICORS-TERAV Network, ISCIII, Madrid, Spain.ORCID 0000-0003-2138-988X
Gemma VilahurResearch Institute Hospital de La Santa Creu I Sant Pau-IIB Sant Pau, and CIBER Enfermedades Cardiovasculares, Barcelona, Spain.ORCID 0000-0002-2828-8873
José Luis ZamoranoUniversity Hospital Ramon Y Cajal, Madrid, Spain.ORCID 0000-0002-0487-1749
Carlos ZaragozaUnidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, Madrid, Spain.ORCID 0000-0002-1706-8592
Peter Ferdinandy *Pharmahungary Group, Szeged, Hungary. peter.ferdinandy@pharmahungary.com.ORCID 0000-0002-6424-6806
Derek J Hausenloy *Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. derek.hausenloy@duke-nus.edu.sg.ORCID 0000-0003-0729-4956

Funding

Centro Nacional de Investigaciones CardiovascularesDeutsche Forschungsgemeinschaft CRC 1116 B8Deutsche Forschungsgemeinschaft RTG 2989Duke-NUS Signature Research Programme Centre Grant scheme (NMRC CG21APR1006)Duke-NUS Signature Research Programme Collaborative Centre Grant scheme (NMRC/CG21APRC006)Duke-NUS Signature Research Programme Singapore Translational Research Investigator Award (MOH-STaR21jun-0003)MOH-STaR21jun-0003European Union COST Action METAHEART CA 22169Hungarian National Scientific Research Fund OTKA-138223Instituto de Salud Carlos III grant PI20/0247Instituto de Salud Carlos III ISCIIILudwig Boltzmann Gesellschaft CARREMMinisterio de Ciencia e InnovaciónMinistry for Innovation and Technology in Hungary 2020-1.1.5-GYORSÍTÓSÁV-2021-00011Ministry for Innovation and Technology in Hungary Hungary"Ministry for Innovation and Technology in Hungary RRF-2.3.1-21-2022-00003 "National Heart LaboratoryPro CNIC FoundationSevero Ochoa Center of Excellence grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033
6 · The paper itself

Abstract

Numerous cardioprotective interventions have been reported to reduce myocardial infarct size (IS) in pre-clinical studies. However, their translation for the benefit of patients with acute myocardial infarction (AMI) has been largely disappointing. One reason for the lack of translation is the lack of rigor and reproducibility in pre-clinical studies. To address this, we have established the European IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) pig AMI network with centralized randomization and blinded core laboratory IS analysis and validated the network with ischemic preconditioning (IPC) as a positive control. Ten sites in the COST Innovators Grant (IG16225) network participated in the IMPACT network. Three sites were excluded from the final analysis through quality control of infarct images and use of pre-defined exclusion criteria. Using a centrally generated randomization list, pigs were allocated to myocardial ischemia/reperfusion (I/R, N = 5/site) or IPC + I/R (N = 5/site). The primary endpoint was IS [% area-at-risk (AAR)], as quantified by triphenyl-tetrazolium-chloride (TTC) staining in a centralized, blinded core laboratory (5 sites), or IS [% left-ventricular mass (LV)], as quantified by a centralized, blinded cardiac magnetic resonance (CMR) core laboratory (2 sites). In pooled analyses, IPC significantly reduced IS when compared to I/R (57 ± 14 versus 32 ± 19 [%AAR] N = 25 pigs/group; p < 0.001; 25 ± 13 versus 14 ± 8 [%LV]; N = 10 pigs/group; p = 0.021). In site-specific analyses, in 4 of the 5 sites, IS was significantly reduced by IPC when compared to I/R when quantified by TTC and in 1 of 2 sites when quantified by CMR. A pig AMI multicenter European network with centralized randomization and core blinded IS analysis was established and validated with the aim to improve the reproducibility of cardioprotective interventions in pre-clinical studies and the translation of cardioprotection for patient benefit.

Indexed as

Ischemic Preconditioning, MyocardialMyocardial InfarctionAnimalsDisease Models, AnimalFemaleMaleMyocardial Reperfusion InjuryReproducibility of ResultsSwineAcute myocardial infarctionIschemia/reperfusion injuryIschemic preconditioningMulticenter networkPigRandomized-controlled trial

Identifiers

PMID39422732
PMCPMC11628588

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.